IMUX · Immunic, Inc. · Metrics
$8.05
+0.44 (+5.78%)
At close · Oct 28
Return incl. dividend (before tax)
Q3 2024 earnings call transcript
Market Cap
$103.83M
Shares
13.64M
Volume · Oct 28
119.82K
Avg daily vol (3M)
327.56K
IMUX metrics
60 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$7.61
Market cap
$103.83M
Price action
20 metricsPrice change (1W)
+2.7%
Price change (30D)
-20.0%
Price change (3M)
-43.0%
Price change (6M)
-29.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
71.8%
Annualized volatility (3M)
72.8%
Beta
1.6
RSI (14D)
40.1
Price vs SMA 50
-29.4%
Price vs SMA 200
—
Avg volume (3M)
327,559
Relative volume
1.1
Average dollar volume
$3.46M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
13.64M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 128.4%
FCF yield
-88.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-112.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$117.88M
Net income (TTM)
−$111.57M
Trailing 12 months
Diluted EPS (TTM)
$-3.54
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+221.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-87.4%
Return on assets
-70.1%
Debt / equity
0.0
Current ratio
5.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$88.05M
Quick ratio
5.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$155.10M
Latest balance sheet
Cash & equivalents
$155.10M
Total assets
$159.17M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$87.72M
Capital expenditures (TTM)
$329,000
R&D (TTM)
$90.64M
SG&A (TTM)
—
Stock compensation (TTM)
$16.17M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
57
13F filer change QoQ
-21
Institutional ownership
63.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
40.3%
Private-fund adviser ownership
35.4%
Active holders' share change QoQ
+50.0%
Holder tenure
6.3
Price vs estimated holder cost
+46.3%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.6%
Short interest
3 metricsShort interest
13.6%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
63 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—